Novartis AG to Acquire Regulus Therapeutics in a Landmark Deal

In a significant move that could transform the treatment landscape for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Novartis AG has entered into an agreement to acquire Regulus Therapeutics Inc. The deal, valued at up to $1.7 billion, marks a pivotal moment in the biopharmaceutical industry.

Financial Details of the Acquisition

Under the terms of the agreement, Novartis will make an initial payment of $7.00 per share, totaling $0.8 billion. Additionally, Regulus shareholders will receive a contingent value right (CVR) offering an extra $7.00 per share, contingent upon the regulatory approval of farabursen, Regulus' lead product candidate.

A New Hope for ADPKD Patients

"This acquisition represents a beacon of hope for patients with ADPKD, who currently face limited treatment options," said Regulus CEO Jay Hagan. "Novartis' global development and commercial expertise is crucial for bringing farabursen to those in need, pending approval."

Next Steps and Expected Timeline

The transaction is pending customary closing conditions and regulatory approvals, with an anticipated completion in the latter half of 2025.